Loading...
Market
Will ivonescimab achieve sales exceeding $500 million by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Summit Therapeutics financial reports and industry sales data
Story
Summit Therapeutics' Ivonescimab Shows PFS of 11.14 Months, Outperforms Merck's Keytruda in PD-L1 Positive Lung Cancer Trial
Sep 8, 2024, 03:30 PM
At the 2024 World Conference on Lung Cancer (WCLC) in San Diego, Summit Therapeutics presented groundbreaking data from their Phase 3 HARMONi-2 trial. The trial revealed that ivonescimab, an investigational therapy, significantly outperformed Merck's Keytruda in treating patients with PD-L1 positive advanced non-small cell lung cancer (NSCLC). Ivonescimab demonstrated a median progression-free survival (PFS) of 11.14 months compared to 5.82 months for Keytruda, reducing the risk of disease progression or death by 49% (HR=0.51, p<0.0001). The objective response rate (ORR) was 50% for ivonescimab versus 38.5% for Keytruda. This data marks a historic achievement in the field of lung cancer treatment, potentially setting a new standard of care.
View original story
Similar markets
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Yes • 50%
No • 50%
